KLK4 and Hepatic fibrosis: Using a protease inhibitor, Camostat Mesilate, we previously demonstrated that plasma kallikrein (PLK) is involved in the TGF-β1 activation associated with liver fibrosis and impaired liver regeneration in animal models (Okuno et al. 2001; Akita et al. 2002).